changes in expression patterns of serum carcinoembryonic antigen at initial diagnosis (ceA in ) and disease progression (ceA pd ) in lung cancer patients under eGfR-tyrosine kinase inhibitors (tKi) treatment may reflect different tumor progression profiles. Of the 1736 lung cancer patients identified from the cancer registry group between 2011 to 2016, we selected 517 patients with advanced stage adenocarcinoma, data on eGfR mutation status and ceA in , among whom were 288 patients with data on ceA pd , eligible for inclusion in the correlation analysis of clinical characteristics and survival. Multivariable analysis revealed that ceA in expression was associated with poor progression-free survival in patients harboring mutant EGFR. Moreover, CEA in and ceA pd were associated with the good and poor post-progression survival, respectively, in the EGFR-mutant group. Cell line experiments revealed that CEA expression and cancer dissemination can be affected by EGFR-TKI selection. EGFR-mutant patients, exhibiting high ceA in (≥5 ng/mL) and low CEA pd (<5 ng/mL), showed a potential toward displaying new metastasis. Taken together, these findings support the conclusion that EGFR mutation status is a critical factor in determining prognostic potential of ceA in and ceA pd in patients under eGfR-tKi treatment, and ceA in and ceA pd are associated with distinct cancer progression profiles.
ceA in as a prognostic marker in adenocarcinoma patients harboring EGFR-mutant. To investigate the possible association between CEA In expression and specific histological subtypes, relevant data from 1183 patients in the lung cancer registry group were subjected to comparison analysis in the various histological subtypes. The results demonstrated that adenocarcinoma was the dominant subtype with a significantly higher CEA In level than other types ( Supplementary Fig. 1A) . A similar analysis of CEA In expression and EGFR mutation status in adenocarcinoma patients (n = 517) revealed that serum CEA In levels were higher in the EGFR-mutant than in the wild-type group ( Supplementary Fig. 1B) .
To evaluate the effect of EGFR mutation status on the prognostic potential of CEA In , adenocarcinoma patients were stratified into either EGFR wild-type (n = 190) or EGFR-mutant (n = 327) groups and subjected to multivariable Cox regression analysis. We found that abnormal CEA In expression was associated with poor PFS only in the EGFR-mutant (CEA In > 100 ng/mL, adjusted hazard ratio [aHR] = 2.39, 95% confidence interval [CI], 1.65-3.45, P < 0.0071) but not in the EGFR wild-type group (Table 2) . Similarly, in EGFR wild-type patients, CEA In expression did not correlate with OS, whereas in patients harboring EGFR mutants, CEA In served as an independent factor that could predict poor prognosis (CEA In > 100 ng/mL, aHR = 1.90, 95% CI, 1.29-2.78, P < 0.0071) ( Table 2) .
Adjusted survival analysis derived from the multivariable Cox model revealed that high CEA In expression correlated with poor PFS and OS in adenocarcinoma patients ( Fig. 2A,B, top) , attesting to the potential of CEA In as a prognostic factor in adenocarcinoma patients. However, when patients were further stratified into EGFR wild-type or mutant groups, the prognostic value of CEA In for PFS and OS was lost in the EGFR wild-type group Figure 1 . Flow chart of patient selection for analysis. Of the 1736 lung cancer patients from the cancer registry group, 517 patients with advanced stage adenocarcinoma had information on CEA In (CEA level at initial diagnosis) and EGFR mutation status, but only 288 (55.7%, 288/517) patients with information on both CEA In and CEA Pd (CEA level at disease progression) were included in correlation analysis of clinical characteristics with survival outcome. CEA In , serum carcinoembryonic antigen level at initial diagnosis; CEA Pd , serum carcinoembryonic antigen level at disease progression; AD, adenocarcinoma of lung, SQ, squamous cell carcinoma of lung; NOS: non-small cell lung cancer-not otherwise specified; SCLC, small cell lung cancer; PFS, progression-free survival; OS, overall survival; PPS, post-progression survival.
but remained in the EGFR-mutant group ( Fig. 2A,B , middle and bottom). In EGFR-mutant group, the mean values (standard deviation) of CEA In in good, moderate and poor histologic grades were 12.6 (28.4), 9 (31.4) , and 19.8 (30.4) ng/mL, respectively, with a P-value of 0.786, suggesting no association of CEA In with histologic grades. These findings indicate that EGFR mutation status is a critical factor in determining the prognostic potential of CEA In . www.nature.com/scientificreports www.nature.com/scientificreports/ and EGFR-mutant (n = 194) groups and subjected to multivariable Cox model. We observed that CEA Pd levels (>100 ng/mL, aHR = 4.39, 95% CI, 2.22-8.70, P < 0.0071; 5-100 ng/mL, aHR = 2.55, 95% CI, 1.48-4.42, P < 0.0071) were significantly correlated with good and poor predicting post-progression survival (PPS), respectively, but only in the EGFR-mutant group and not in the wild-type group (Table 3) . Further, adjusted survival analysis derived from the multivariable Cox model showed that high CEA Pd expression correlated with poor PPS in patients harboring EGFR mutations, whereas high CEA In expression was associated with good PPS in patients harboring EGFR mutations (Fig. 3A,B) . Moreover, we observed that different EGFR-TKI treatments (gefitinib, erlotinib, or afatinib) did not have significant differences on PFS and PPS (Supplementary Table 1 ). These findings indicate that CEA Pd level would be an effective prognostic marker of PPS, especially in adenocarcinoma patients harboring EGFR mutations. Moreover, the observation that CEA Pd and CEA In levels predict different PPS suggests that EGFR-TKI treatment leads to changes in CEA expression patterns.
eGfR-tKi treatment affects ceA expression and dissemination property of lung cancer cells. The hypothesis that EGFR-TKI treatment can affect CEA expression was based on the case of a
55-year-old male, who was initially diagnosed with clinical stage IV adenocarcinoma. The primary tumor was found in the left upper lobe of the lung and metastatic lesions were seen in the bone (Fig. 4A ). The patient harbored EGFR-L858R mutation, and serum CEA level at initial diagnosis was 32.77 ng/mL. Four months of EGFR-TKI treatment with gefitinib led to decreased tumor size and normalization of serum CEA levels. Seven months later, the tumor progressed with an enlarged primary tumor and newly developed metastases in the brain and the C spine. However, serum CEA levels remained normal. Therefore, to test whether EGFR-TKI treatment affects CEA expression pattern and dissemination ability of lung cancer cells harboring EGFR mutations, we treated EGFR-mutant HCC827 (delE746_A750) lung adenocarcinoma cells with increasing concentrations of gefitinib. Surviving cells were pooled together, propagated, and labeled HCC827GR. No EGFR-T790M mutation Table 3 . Association between clinical characteristics and post-progression survival among 288 patients with advanced stage lung adenocarcinoma and available data of CEA In and CEA Pd , stratified by EGFR mutation status. HR, hazard ratio; aHR, adjusted hazard ratio; CI, confidence interval; EGFR, epidermal growth factor receptor; CEA In , serum carcinoembryonic antigen level at initial diagnosis; CEA Pd , serum carcinoembryonic antigen level at disease progression; * Statistically significant after a Bonferroni adjustment at P < 0.0071. www.nature.com/scientificreports www.nature.com/scientificreports/ was detected in the HCC827GR cells (data not shown). We observed that while HCC827GR cells had a much higher IC 50 for gefitinib, compared to the parental HCC827 cells, CEA expression was lost and migration and invasion abilities were increased in HCC827GR cells (Fig. 4B) . The cell viability assay demonstrated that HCC827GR cells are more sensitive to pemetrexed than HCC827 cells (Fig. 4B) . These data indicate that EGFR-TKI treatment can change CEA expression pattern and affect dissemination and chemoresistant properties of lung cancer cells. correlation between ceA expression pattern and new metastasis during tKi treatment and disease progression. To further confirm whether EGFR-TKI treatment affects CEA expression and metastasis in patients, we divided EGFR-mutant lung cancer patients into four groups based on their CEA In (CEA In < 5 ng/ mL or CEA In ≥ 5 ng/mL) and CEA Pd levels (CEA Pd < 5 ng/mL or CEA Pd ≥ 5 ng/mL). We observed that patients with higher CEA In (≥5 ng/mL) but normal CEA Pd levels (<5 ng/mL) exhibited a greater trend toward development of new metastasis after EGFR-TKI treatment compared to other groups (Fig. 5A ). Remaining survival analysis after disease progression in these four groups of patients revealed that patients in group 3 (CEA In ≥ 5 ng/ mL and CEA Pd < 5 ng/mL) had a better PPS than other groups (Fig. 5B) . These data support the notion that EGFR-TKI treatment affects CEA expression patterns and indicate that this change confers distinct survival and metastatic properties.
Discussion
EGFR-TKI targeted therapy is one of the major treatment modalities in lung cancer. However, whether EGFR mutation status and EGFR-TKI treatment affect the prognostic potential of CEA, both before and after disease progression, remains less understood. Here, we demonstrate that CEA In is a prognostic factor associated with poor PFS and OS in patients harboring EGFR mutations but not in those with wild-type EGFR. Further, CEA In www.nature.com/scientificreports www.nature.com/scientificreports/ and CEA Pd can serve as prognostic factors associated with good or poor PPS, respectively. We also show that, in lung cancer patients harboring EGFR mutations, the divergent CEA In and CEA Pd pattern (CEA In ≥ 5 ng/mL and CEA Pd < 5 ng/mL) is associated with new metastasis. Our results provide insights into CEA heterogeneity subsequent to EGFR-TKI treatment and may reflect oligoclonality of lung tumors with distinct progression patterns.
A previous immunohistochemistry analysis of early stage lung tumors revealed that CEA expression is higher in lung adenocarcinoma than squamous cell carcinoma 24 . We also show that adenocarcinoma patients exhibit higher serum CEA In levels than squamous cell carcinoma patients or small cell lung cancer patients in the late stage. Additionally, the EGFR-mutant group had higher CEA In levels than the wild-type group. Several reports have stated that CEA In levels can serve as a prognostic factor associated with poor survival in NSCLC after chemotherapy or surgery, while others have indicated that CEA In did not predict survival [25] [26] [27] [28] [29] [30] [31] . Cai reported that high CEA In level (>5 ng/mL) was associated with EGFR mutation status and correlated with poor OS in stage I-IIIA NSCLC patients, who were not divided into EGFR-wild and mutant groups 32 . Zhao et al. found that high CEA In level (>10 ng/mL) was associated with poor PFS and OS in stage IIIB/IV NSCLC patients with EGFR-mutations, whereas the association between CEA In level with survival in the EGFR-wild group was not addressed 33 . Here, we report that higher CEA In levels (CEA In 5-100 ng/mL and CEA In > 100 ng/mL) are associated with poor PFS and OS in stage IIIB/IV patients with adenocarcinoma. While stratifying adenocarcinoma patients into EGFR-mutant and wild-type groups, who were under EGFR-TKI and chemotherapies before diseases progression, respectively, we observed that CEA In prognostic power was evident only in the EGFR-mutant group but not in the wild-type group. Our data reveal that higher CEA In levels are associated with poor disease progression and three groups (CEA In < 5 ng/mL, CEA In 5-100 ng/mL, and CEA In > 100 ng/mL) show distinct survival outcomes under EGFR-TKI treatment. Resistance toward first-and second-generation EGFR-TKI treatment can be attributed to EGFR-T790M-dependent and independent mechanisms [14] [15] [16] [17] [18] . Patients with non-EGFR-T790M tumors tend to develop new metastasis after EGFR-TKI treatment, implying the presence of differential oncogenic properties in EGFR-TKI-resistant lung cancer cells 34 .
As CEA levels may be affected by treatments for tumor progression, we also evaluated the prognostic value of CEA Pd levels at the time of first disease progression and show that CEA Pd is an independent factor associated with PPS. Moreover, when CEA Pd is accounted for, CEA In correlates with good PPS. Further, sub-stratification of adenocarcinoma into EGFR-mutant and wild-type groups revealed that the prognostic powers of CEA In and CEA Pd in predicting PPS were statistically significant in the EGFR-mutant group but not in the wild-type group. These observations imply that frequent assessments of CEA level may serve as an effective prognostic tool in adenocarcinoma patients with EGFR mutations. To the best of our knowledge this is the first report that shows distinct roles for initial baseline CEA in predicting survival before and after disease progression.
Whether CEA can serve as an effective marker for monitoring TKI treatment in EGFR-mutant lung adenocarcinoma is questionable because CEA heterogeneity may lead to contradictory results from different studies. By selecting EGFR-TKI resistant lung cancer cells in vitro, we could monitor changes in CEA heterogeneity in CEA-positive lung adenocarcinoma cells during gefitinib treatment. Using cell line models, we found that clones resistant to EGFR-TKI treatment lost CEA expression, and demonstrated increased migration and decreased pemetrexed chemoresistant properties. These data point to the presence of CEA heterogeneity and suggest that it can be affected by EGFR-TKI treatment. It has been reported that EGFR-TKI treatment can select CEA-positive clones from a CEA-negative primary tumor, resulting in tumor progression 23 . To further understand the role of CEA heterogeneity in lung tumors, we divided adenocarcinomas with EGFR mutations into four groups based on CEA In and CEA Pd levels and discovered that patients displaying high CEA In but low CEA Pd levels tended to develop new metastasis. Further, patients with low CEA In but high CEA Pd tended to have worse PPS. Many enrolled patients with disease progression after TKI treatment received pemetrexed chemotherapy. These findings support the notion that CEA expression patterns in patients can be altered by TKI treatment, and patients with changes in expression patterns of CEA In and CEA Pd may exhibit different responses toward subsequent chemotherapies after the EGFR-TKI treatment. We have previously reported that tumor heterogeneity is in part regulated by epigenetic control to generate lung cancer cells with distinct dissemination and chemoresistant properties 35 . Whether heterogeneous CEA expression patterns and related oncogenic properties in lung cancer cells are under epigenetic control requires further investigation.
Although we demonstrate a significant prognostic potential for CEA, there are limitations to our study, such as its single-institution retrospective design. Next, data were extracted from the lung cancer registry group of the Tri-Service General Hospital. Although patients were treated in accordance with national guidelines for lung cancer, they were treated by different physicians and departments, which may have led to different clinical management and outcomes. Besides, CEA Pd data were not available for 229 of 517 patients with known EGFR status, and thus the results might be skewed. Although multivariable analysis revealed that CEA Pd is independently associated with PPS in EGFR-mutant but not in wild-type group, the high aHR (1.92) of CEA Pd (>100 ng/mL) in the wild-type group could be due to the low patient numbers. Moreover, records on T790M status in our study cohort were incomplete, and thus the changes in expression patterns of CEA In and CEA Pd cannot be correlated with T790M-dependent and -independent resistance mechanisms. Further, as whole-body imaging was not routinely performed in every patient, new metastatic sites may have been missed. We did not control for other factors that can lead to a false-positive increase in CEA, such as smoking, infections, inflammatory bowel disease, pancreatitis, cirrhosis of the liver, and some benign tumors in the organs in which an elevated CEA level indicates cancer.
To summarize, our findings indicate that CEA expression is associated with EGFR mutation status, and that its prognostic potential is limited to patients harboring EGFR mutations. Additionally, CEA heterogeneity can be affected by EGFR-TKI treatment. Changes in CEA expression patterns between inital diagnosis and disease progression may reflect oligoclonality of lung cancer cells with distinct chemoresistant and metastatic properties conferred by EGFR-TKI treatment.
Materials and Methods
Patients and samples. Records of patients (N = 1736) with lung cancer, registered at the cancer registry group, Tri-Service General Hospital, National Defense Medical Center, between January 2011 and January 2016, were screened. Patients were excluded if they had more than one primary cancer, no data on EGFR mutation or CEA levels, or if they did not undergo EGFR-TKI treatment while harboring an EGFR mutation. Patients with histologically or cytologically confirmed stage IIIB-IV adenocarcinoma of the lung were eligible for inclusion and data were collected from 517 patients by retrospective chart review, with a data cutoff limit of September 2018 for outcome. This retrospective study was conducted with the approval of the Joint Institutional Review Board of the Tri-Service General Hospital (Approved number 1-107-05-146). The need for informed consent was waived, and all methods were performed in accordance with the relevant guidelines and regulations. Serum CEA (normal range: 0-5 ng/mL) was routinely measured via an electrochemiluminescence immunoassay on an automatic analyzer (CEA-RIACT Cisbio Bioassays, France) at the time of diagnosis of lung cancer and disease progression according to the manufacture instruction. EGFR mutation analysis on tissue biopsy samples was performed at diagnosis using the ROCHE cobas EGFR Mutation Test kit according to the manufacture instruction. Patients with detectable EGFR exon 19-21 mutations were placed in the EGFR-mutant group. Patients with no detectable EGFR mutations were categorized as the EGFR wild-type group. Chest computed tomography was performed every three months in patients to monitor the cancer progression according to the policy of National Health Insurance. All selected patients with stage IIIB-IV disease and mutated-EGFR received EGFR-TKI (gefitinib, erlotinib, or afatinib) as first-line treatment during the study period. Most of them received platinum plus pemetrexed therapy after developing resistance to EGFR-TKI.
Cell line assays. HCC827 cells were initially obtained from the American Type Culture Collection and later certified via STR-PCR DNA profiling and EGFR sequencing analysis. HCC827GR cells were established in our laboratory by exposing HCC827 cells to stepwise and incremental concentrations of gefitinib 18 . Surviving cells were pooled, propagated, and labeled HCC827GR. Cell culture, IC 50 analysis, qPCR, migration and invasion assays were performed as described previously 18 . CEA ELISA was performed using human CEA ELISA kit (General Biologicals, Taiwan) according to the manufacture instruction.
Statistical analysis. The difference in CEA In levels among lung cancer subtypes or EGFR mutations was analyzed by the Kruskal-Wallis test followed by Bonferroni-adjusted multiple comparison or the Mann-Whitney U test, as needed. The associations between CEA, EGFR mutation status, progression-free survival (PFS), overall survival (OS), and post-progression survival (PPS) were determined using Cox regression analysis. Correlation analyses between CEA In , CEA Pd , and new metastasis in patients with advanced stage lung adenocarcinoma were performed using Fisher's exact test. Progression-free survival (PFS) is defined as the time from the first EGFR-TKI administration to the date of first radiological confirmed progression. The post-progression survival (PPS) is defined as the time from the end of the last EGFR-TKI administration to the date of death. Overall survival (OS) is defined as the time from the first EGFR-TKI administration to the to the date of death.
There were a total of seven multiple testing results regarding the OS, PFS or PPS (Tables 2-3 and Fig. 5 ); therefore, a Bonferroni adjustment of type I error was done and a two-sided P value lower than 0.0071 (0.05/7) was considered statistically significant. Data analyses were conducted using SPSS ver.22 (Armonk, NY: IBM Corp).
